双重免疫检查点阻塞诱导了功能障碍的CD8+T细胞和激活的Treg区间的类似变化
Anne M van der Leun1, Joleen J H Traets2, Joris L Vos3
1Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Cancer discovery
|August 7, 2023
概括
新辅助药在头癌中的PD-1/CTLA4阻断改变T细胞的形状. 响应者显示调节性T细胞 (Tregs) 减少和CD8+T细胞改善,而非响应者增加了自然杀手细胞.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症研究 癌症研究
背景情况:
- 头部和部状细胞癌 (HNSCC) 显示新辅助PD-1/CTLA4阻断的响应率为20%-35%.
- 对瘤抗原的T细胞识别对于HNSCC的免疫治疗反应至关重要.
- 了解与反应和抵抗相关的T细胞状态变化是很重要的.
研究的目的:
- 分析新辅助剂PD-1和CTLA4阻断对未经治疗的HNSCC中瘤内T细胞的影响.
- 为了识别与对双重免疫疗法的反应和抵抗相关的免疫细胞变化.
主要方法:
- 来自HNSCC患者的原发性瘤免疫透物的分析.
- 响应和不响应患者之间的免疫细胞概况的比较.
- 评估T细胞激活,调控和功能障碍标志物.
主要成果:
- 活性与非活性调节性CD4+T细胞 (Tregs) 的较高基线比率与免疫治疗反应相关.
- 响应的患者在治疗后的活性Tregs显著下降.
- 响应的患者在CD8+ T细胞中表现出活性/功能障碍基因的减少表达.
- 没有反应的患者表现出自然杀手细胞细胞毒性早期增加.
结论:
- 双重PD-1/CTLA4阻断诱导了响应HNSCC患者Treg和CD8+T细胞区的并行重塑.
- 基线活性Tregs可能与对新辅助免疫疗法的反应有关.
- 在治疗早期的响应者与非响应者之间观察到不同的免疫特征.
相关概念视频
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
T Cell Activation and Clonal Selection
808
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
808
Cell-mediated Immune Responses
68.9K
Overview
68.9K
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
Cytotoxic T Cells-mediated Immune Response
971
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
971


